Actively Recruiting
AI-assisted Migraine Education: Efficacy, Safety and Patients' Acceptance
Led by Ente Ospedaliero Cantonale, Bellinzona · Updated on 2026-03-12
140
Participants Needed
1
Research Sites
143 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Migraine affects 1 in 7 people globally, significantly impacting quality of life and economic productivity. Despite its prevalence, limited awareness leads to misdiagnosis, inadequate treatment, and stigmatization. AI can enhance migraine management through improved diagnosis, prediction, and personalized education. The primary objective of this study is to determine if adding AI-assisted migraine education to standard education improves patients' understanding of their condition more effectively.
CONDITIONS
Official Title
AI-assisted Migraine Education: Efficacy, Safety and Patients' Acceptance
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged between 18 and 65 years at the time of signing the informed consent
- Newly diagnosed with migraine confirmed through medical records
- Able to provide signed informed consent
- Access to a laptop, computer, smartphone, or tablet
You will not qualify if you...
- Insufficient knowledge of the study language (Italian)
- Cognitive impairment or inability to use or access the AI learning platform
- Vulnerable participants such as minors, those incapable of judgment, or under tutelage
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ente Ospedaliero Cantonale - Ospedale Regionale di Lugano
Lugano, Switzerland
Actively Recruiting
Research Team
G
Giulia Mallucci, Prof. Dr.ssa med.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here